-
- Supports brain function and cognitive performance
- Supports mood
- Supports cholinergic neurotransmission
- Supports energy metabolism
- Supports healthy aging
- Supports neuroprotection
Acetyl-L-Carnitine (ALCAR) is one type of acetylated L-carnitine.
As a result, ALCAR tends to be preferred when it comes to supporting the brain and nervous system since it more readily crosses the blood-brain barrier.
According to some studies, ALCAR is more bioavailable than L-carnitine.
Because carnitine was originally found in meat extracts, the name is derived from Latin carnus (flesh).
Carnitine is consumed by adults who eat animal products in amounts between 60 and 180 milligrams. Vegetarianset about 10–12 milligrams less [1], and vegans get a bit more because they consume dairy products.
It performs the same functions as ALCAR. Carnitine plays a vital role in mitochondrial fat metabolism—it is responsible for transporting long-chain fatty acids across the mitochondrial membrane to be broken down by multienzyme β-oxidation.
Through this process, fats and oils from our diet are used for energy production, and mitochondrial capacity to burn fat is enhanced. ALCAR supports acetylcholine synthesis, unlike L-carnitine, which does not contain an acetyl group, as the acetyl group can be transferred to coenzyme A to produce acetyl-CoA, which is then converted into the neurotransmitter acetylcholine.
The Krebs cycle in the mitochondria uses acetyl-CoA as a primary substrate, which is essential for ATP production.
Multiple studies have indicated that ALCAR enhances cholinergic neurotransmission and supports brain energy metabolism; it has also been shown to exert significant neuroprotective effects [2–5].
Brain and cognitive function
Mood
Physical strength and fatigue
Mitochondrial function
Healthy aging and longevity
Get Instant Access To A Simple, Proven System That Has Helped
THOUSANDS of People
IGNITE Their Health and Energy
to Create The Life They Deserve!
[1]C.J. Rebouche, Ann. N. Y. Acad. Sci. 1033 (2004) 30–41.
[2]H. Kuratsune, Y. Watanabe, K. Yamaguti, G. Jacobsson, M. Takahashi, T. Machii, H. Onoe, K. Onoe, K. Matsumura, S. Valind, T. Kitani, B. Långström, Biochem. Biophys. Res. Commun. 231 (1997) 488–493.
[3]K.A. Nałecz, D. Miecz, V. Berezowski, R. Cecchelli, Mol. Aspects Med. 25 (2004) 551–567.
[4]L.L. Jones, D.A. McDonald, P.R. Borum, Prog. Lipid Res. 49 (2010) 61–75.
[5]D.W. Foster, Ann. N. Y. Acad. Sci. 1033 (2004) 1–16.
[6]M. Malaguarnera, M. Vacante, M. Motta, M. Giordano, G. Malaguarnera, R. Bella, G. Nunnari, L. Rampello, G. Pennisi, Metab. Brain Dis. 26 (2011) 281–289.
[7]S. Singh, A. Mishra, N. Srivastava, R. Shukla, S. Shukla, Mol. Neurobiol. 55 (2018) 583–602.
[8]S.A. Montgomery, L.J. Thal, R. Amrein, Int. Clin. Psychopharmacol. 18 (2003) 61–71.
[9]J.O. Brooks 3rd, J.A. Yesavage, A. Carta, D. Bravi, Int. Psychogeriatr. 10 (1998) 193–203.
[10]B.N. Ames, J. Liu, Ann. N. Y. Acad. Sci. 1033 (2004) 108–116.
[11]M. Malaguarnera, M.P. Gargante, E. Cristaldi, V. Colonna, M. Messano, A. Koverech, S. Neri, M. Vacante, L. Cammalleri, M. Motta, Arch. Gerontol. Geriatr. 46 (2008) 181–190.
[12]R.C.W. Vermeulen, H.R. Scholte, Psychosomatic Medicine 66 (2004) 276–282.
[13]V. Dolezal, S. Tucek, J. Neurochem. 36 (1981) 1323–1330.
[14]S. Tucek, in: S.-M. Aquilonius, P.-G. Gillberg (Eds.), Progress in Brain Research, Elsevier, 1990, pp. 467–477.
[15]O.B. Smeland, T.W. Meisingset, K. Borges, U. Sonnewald, Neurochem. Int. 61 (2012) 100–107.
[16]T. Aureli, A. Miccheli, R. Ricciolini, M.E. Di Cocco, M.T. Ramacci, L. Angelucci, O. Ghirardi, F. Conti, Brain Res. 526 (1990) 108–112.
[17]T. Aureli, M.E. Di Cocco, C. Puccetti, R. Ricciolini, M. Scalibastri, A. Miccheli, C. Manetti, F. Conti, Brain Res. 796 (1998) 75–81.
[18]C. Ori, U. Freo, G. Pizzolato, M. Dam, Brain Res. 951 (2002) 330–335.
[19]U. Freo, M. Dam, C. Ori, Brain Res. 1259 (2009) 32–39.
[20]R.F. Villa, F. Ferrari, A. Gorini, Neurochem. Res. 36 (2011) 1372–1382.
[21]T. Aureli, A. Miccheli, M.E. Di Cocco, O. Ghirardi, A. Giuliani, M.T. Ramacci, F. Conti, Brain Res. 643 (1994) 92–99.
[22]R.E. Rosenthal, R. Williams, Y.E. Bogaert, P.R. Getson, G. Fiskum, Stroke 23 (1992) 1312–7; discussion 1317–8.
[23]H. Sershen, L.G. Harsing Jr, M. Banay-Schwartz, A. Hashim, M.T. Ramacci, A. Lajtha, J. Neurosci. Res. 30 (1991) 555–559.
[24]L.G. Harsing Jr, H. Sershen, E. Toth, A. Hashim, M.T. Ramacci, A. Lajtha, Eur. J. Pharmacol. 218 (1992) 117–121.
[25]R. Laschi, L. Badiali de Giorgi, F. Bonvicini, L. Centurione, Int. J. Clin. Pharmacol. Res. 10 (1990) 59–63.
[26]K. Kocsis, R. Frank, J. Szabó, L. Knapp, Z. Kis, T. Farkas, L. Vécsei, J. Toldi, Neuroscience 332 (2016) 203–211.
[27]T. Aureli, M.E. Di Cocco, G. Capuani, R. Ricciolini, C. Manetti, A. Miccheli, F. Conti, Neurochem. Res. 25 (2000) 395–399.
[28]S. Singh, A. Mishra, S.K. Mishra, S. Shukla, Neurochem. Int. 108 (2017) 388–396.
[29]S.A. Zanelli, N.J. Solenski, R.E. Rosenthal, G. Fiskum, Ann. N. Y. Acad. Sci. 1053 (2008) 153–161.
[30]Y. Liu, R.E. Rosenthal, P. Starke-Reed, G. Fiskum, Free Radic. Biol. Med. 15 (1993) 667–670.
[31]S. Afshin-Majd, K. Bashiri, Z. Kiasalari, T. Baluchnejadmojarad, R. Sedaghat, M. Roghani, Biomed. Pharmacother. 89 (2017) 1–9.
[32]H. Keshavarz-Bahaghighat, M.R. Sepand, M.H. Ghahremani, M. Aghsami, N. Sanadgol, A. Omidi, V. Bodaghi-Namileh, O. Sabzevari, Biol. Trace Elem. Res. 184 (2018) 422–435.
[33]L. Nicassio, F. Fracasso, G. Sirago, C. Musicco, A. Picca, E. Marzetti, R. Calvani, P. Cantatore, M.N. Gadaleta, V. Pesce, Exp. Gerontol. 98 (2017) 99–109.
[34]G. Forloni, N. Angeretti, S. Smiroldo, J. Neurosci. Res. 37 (1994) 92–96.
[35]M.A. Virmani, V. Caso, A. Spadoni, S. Rossi, F. Russo, F. Gaetani, Ann. N. Y. Acad. Sci. 939 (2006) 162–178.
[36]S. Chiechio, P.L. Canonico, M. Grilli, Int. J. Mol. Sci. 19 (2017).
[37]N. Veronese, B. Stubbs, M. Solmi, O. Ajnakina, A.F. Carvalho, S. Maggi, Psychosom. Med. 80 (2018) 154–159.
[38]S.-M. Wang, C. Han, S.-J. Lee, A.A. Patkar, P.S. Masand, C.-U. Pae, J. Psychiatr. Res. 53 (2014) 30–37.
[39]G. Garzya, D. Corallo, A. Fiore, G. Lecciso, G. Petrelli, C. Zotti, Drugs Exp. Clin. Res. 16 (1990) 101–106.
[40]E. Tempesta, L. Casella, C. Pirrongelli, L. Janiri, M. Calvani, L. Ancona, Drugs Exp. Clin. Res. 13 (1987) 417–423.
[41]R. Zanardi, E. Smeraldi, Eur. Neuropsychopharmacol. 16 (2006) 281–287.
[42]G. Bersani, G. Meco, A. Denaro, D. Liberati, C. Colletti, R. Nicolai, F.S. Bersani, A. Koverech, Eur. Neuropsychopharmacol. 23 (2013) 1219–1225.
[43]P. Leombruni, M. Miniotti, F. Colonna, C. Sica, L. Castelli, M. Bruzzone, S. Parisi, E. Fusaro, P. Sarzi-Puttini, F. Atzeni, R.G. Torta, Clin. Exp. Rheumatol. 33 (2015) S82–5.
[44]M. Malaguarnera, R. Bella, M. Vacante, M. Giordano, G. Malaguarnera, M.P. Gargante, M. Motta, A. Mistretta, L. Rampello, G. Pennisi, Scand. J. Gastroenterol. 46 (2011) 750–759.
[45]B.T. Wall, F.B. Stephens, D. Constantin-Teodosiu, K. Marimuthu, I.A. Macdonald, P.L. Greenhaff, J. Physiol. 589 (2011) 963–973.
[46]A. Gorini, A. D’Angelo, R.F. Villa, Neurochemical Research 23 (1998) 1485–1491.
[47]P. Cassano, A.G. Sciancalepore, V. Pesce, M. Flück, H. Hoppeler, M. Calvani, L. Mosconi, P. Cantatore, M.N. Gadaleta, Biochim. Biophys. Acta 1757 (2006) 1421–1428.
[48]V. Calabrese, A.M. Giuffrida Stella, M. Calvani, D.A. Butterfield, J. Nutr. Biochem. 17 (2006) 73–88.
GET THE LATEST, MOST EFFECTIVE TOOLS, STRATEGIES & PRACTICES
Access The World's Best Strategies & Tools To Unlock Your Potential
CAAN Innovations Ltd. | Registered Address: 124 City Road London EC1V 2NX | Company Number: 10670078
Statements made on this website have not been evaluated by DEFRA or the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.